The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. ##STR00001##

The present invention provides chimeric compounds that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CK1-alpha activity and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as cytokine-mediated diseases, disorders, and conditions, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant rejection, and cancer, are provided.

The present invention provides chimeric compounds that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CK1-alpha activity and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as cytokine-mediated diseases, disorders, and conditions, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant rejection, and cancer, are provided.

Imidazophenanthridine ligands and metal complexes are provided. The compounds exhibit improved stability through a linking substitution that links a nitrogen bonded carbon of an imidizole ring to a carbon on the adjacent fused aryl ring. The compounds may be used in organic light emitting devices, particularly as emissive dopants, providing devices with improved efficiency, stability, and manufacturing. In particular, the compounds provided herein may be used in blue devices having high efficiency.

Compounds having the formula I wherein R.sup.1, X.sup.1, X.sup.2, X.sup.3 and X.sup.4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders. ##STR00001##

Compounds having the formula I wherein R.sup.1, X.sup.1, X.sup.2, X.sup.3 and X.sup.4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders. ##STR00001##

The present disclosure provides an organic compound represented by general formula (1):

##STR00001##

(In general formula (1), R.sub.1 to R.sub.20 are each independently selected from the group consisting of a hydrogen atom, a deuterium atom, halogen atoms, alkyl groups, alkoxy groups, silyl groups, amino groups, aryl groups, heteroaryl groups, and a cyano group. R.sub.1 to R.sub.20 may be bonded to one another to form a ring and, optionally, via a chalcogen atom. At least a combination R.sub.9 and R.sub.10 or R.sub.19 and R.sub.20 forms a bond. X.sub.1 and X.sub.2 are each independently selected from the group consisting of chalcogen atoms, methylene groups, and silylene groups.)

The present disclosure provides an organic compound represented by general formula (1):

##STR00001##

(In general formula (1), R.sub.1 to R.sub.20 are each independently selected from the group consisting of a hydrogen atom, a deuterium atom, halogen atoms, alkyl groups, alkoxy groups, silyl groups, amino groups, aryl groups, heteroaryl groups, and a cyano group. R.sub.1 to R.sub.20 may be bonded to one another to form a ring and, optionally, via a chalcogen atom. At least a combination R.sub.9 and R.sub.10 or R.sub.19 and R.sub.20 forms a bond. X.sub.1 and X.sub.2 are each independently selected from the group consisting of chalcogen atoms, methylene groups, and silylene groups.)

The present invention provides chimeric compounds that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CK1-alpha activity and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as cytokine-mediated diseases, disorders, and conditions, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant rejection, and cancer, are provided.

The present invention discloses pyridoinolobenzo[b,e]diazepine and thiazepine derivatives of Formula 1, ##STR00001##
wherein X is NR.sup.10, S, S(O), or S(O).sub.2. Y is a single bond or no bond. A and B are independently (CH.sub.2).sub.m and (CH.sub.2).sub.n respectively; and the subscripts m and n independently vary from 1 to 4. R.sup.1 to R.sup.9 are various electron donating, electron withdrawing, hydrophilic, or lipophilic groups selected to optimize the physicochemical and biological properties of compounds of Formula I.